Identifying inflammation is at the heart of the matter

Longevity Technology: Oxford-based Caristo Diagnostics has developed an AI solution that can detect and quantify coronary inflammation, a primary driver of coronary artery disease. CaRi-Heart® can detect previously invisible coronary inflammation in routine CCTA scans meaning anti-inflammatory therapeutics can be administered.

Longevity Technology interviewed Frank Cheng, CEO of Caristo Diagnostics, to find out more about this world-first technology which is already in use in multiple NHS trusts and private hospitals in the UK, Europe and Australia and in the process of securing FDA approval for use in the US. Read the entire feature here.